Introduction

Recent advances in the diagnosis and staging of non-small-cell lung cancer (NSCLC) have led to more precise characterization of stage III disease. Current 8th TNM staging classification recognizes stage III NSCLC as three different groups: IIIA, IIIB and IIIC (1). These categories differ substantially in terms of treatment options and outcomes, but in all instances curative approaches usually include multimodality treatment consisting of radiotherapy (RT) and/or surgery combined with chemotherapy (CT) (2). Whereas surgical options are frequently attempted for patients with stage IIIA, the remaining two groups are typically managed with RT, in most cases combined with sequential or concomitant CHT. Several clinical studies and meta-analyses have documented concomitant chemoradiotherapy (CHRT) as the most effective...
definitive treatment in locally advanced inoperable NSCLC, and this strategy constitutes the current standard in this setting. The median overall survival (OS) with CHRT in clinical trials performed in the past decade was in the range of 20–30 months, with five-year OS of approximately 30% (Table 1) (3-10). The recent PACIFIC study demonstrated that these outcomes may be considerably improved with the addition of maintenance durvalumab, a monoclonal anti-PD-L1 agent (10) (RT-immunotherapy combinations are addressed in another article of this issue). Recent progress in treatment outcomes of locally advanced NSCLC has been achieved mainly by improvements in diagnostic and staging tools and advanced RT techniques. This article will summarize these developments and provide the rationale for further efforts to increase locoregional control and OS with CHRT. We present the following article in accordance with the Narrative Review reporting checklist (available at [http://dx.doi.org/10.21037/tlcr-20-704](http://dx.doi.org/10.21037/tlcr-20-704)).

### Methods

Literature searches of the MEDLINE® and PubMed® databases were carried out to identify journal articles published before May 2020. The following key words were used and combined to search the databases: ‘stage III lung cancer’, ‘stage III NSCLC’, ‘chemoradiotherapy’, ‘chemoradiation’. Publications detailing phase II or III studies, retrospective analyses and meta-analyses relevant to reviewed topic were identified.

### Improvements in diagnosis and staging

Patients who are histologically or cytologically diagnosed with lung cancer should undergo a quick, yet thorough staging. Approximately one-third of NSCLC patients present with stage III disease (2) and are candidates for various multimodality approaches. Within the past two decades several important diagnostic tools have been largely implemented in NSCLC. These include mediastinal staging with ultrasound-guided transbronchial or transesophageal needle aspiration biopsy (EBUS and EUS TBNA, respectively), which largely replaced mediastinoscopy, computed tomography (CT), magnetic resonance (MR) of the brain, and 18-fluoro-D-glucose positron emission tomography coupled with computed tomography (18F-FDG PET-CT). Other staging procedures are employed depending on particular symptoms or findings. For example, video thoracostomy is performed in patients with pleural effusion, and chest MR in those with chest wall or spine invasion. More accurate anatomical information on the tumor extent results in upstaging of presumed stage III in a substantial proportion of patients, and allows for more precise treatment delivery. The degree by which these diagnostic developments might have influenced the outcomes of concurrent CHRT is summarized below.

**18FDG PET-CT**

Within the past decade, 18FDG PET-CT for lung cancer staging and RT planning has been implemented in most institutions, and is currently a part of international guidelines (11,12). Examples of particular usefulness of this diagnostic tool in accurate delineation of primary tumor extent are post-obstructive atelectasis or chest wall invasion (13). 18FDG PET-CT is also more accurate than conventional CT in the assessment of mediastinal lymph nodes. The meta-analysis of 39 studies demonstrated that the median sensitivity and specificity of 18F-FDG PET-CT for the detection of lymph node involvement was 85% and 90%, respectively, compared with 61% and 79%, respectively, for CT alone (14). In the recent PET-Plan phase III trial, stage III NSCLC patients were allocated to definitive CHRT to target volume delineation informed by 18F-FDG PET-CT with or without elective nodal irradiation (ENI) (15). Isotoxic dose escalation was allowed from 60 to 74 Gy, with 2 Gy per fraction. The cumulative incidence of locoregional progression at one year was more than two-fold lower in the latter group [per protocol analysis, 14% (95% CI: 5–21%) vs. 29% (95% CI: 17–38%); HR =0.57 (95% CI: 0.30–1.06)], respectively, with similar risk of out-of-field recurrence (below 10% in both arms). Thus, RT planning based on 18FDG PET-CT, with omission of PET-negative lymph nodes, may be considered a current standard of care. A note of caution, however, should be made for PET-CT negative or enlarged lymph nodes (more than 10 mm in short axis), which should always be subjected to pathological staging with EBUS, EUS or mediastinoscopy, depending on their location.

18F-FDG PET-CT has a well-proven value for the detection of asymptomatic distant metastases. In stage III NSCLC, after 18F-FDG PET approximately 20–30% of patients are upstaged to stage IV, and this procedure is the main cause of stage migration. A prospective two-cohort study including stage III NSCLC patients considered for neoadjuvant CHRT followed by surgery demonstrated...
Table 1 Results of modern concurrent radiochemotherapy clinical trials for stage III NSCLC. For particular trials, study arms representative for current standard of care were selected.

<table>
<thead>
<tr>
<th>Trial (reference)</th>
<th>N</th>
<th>RT dose and fractionation</th>
<th>CHT schedule</th>
<th>Median PFS (months)</th>
<th>Median OS (months)</th>
<th>Long-term OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROCLAIM; experimental arm (3)</td>
<td>283</td>
<td>60–66 Gy/30–33 fx</td>
<td>Pemetrexed 500 mg/m² iv plus cisplatin 75 mg/m² q. 3 wks (3 cycles) concurrently with RT, followed by 4 cycles of pemetrexed 500 mg/m² iv q. 3 wks</td>
<td>11.4</td>
<td>26.8</td>
<td>40% at 3 years</td>
</tr>
<tr>
<td>PROCLAIM; control arm (3)</td>
<td>272</td>
<td>60–66 Gy/30–33 fx</td>
<td>Etoposide 50 mg/m² iv d. 1–5 q. 4 wks, followed by cisplatin 50 mg/m² d. 1 and 8 (2 cycles) concurrently with RT, followed by 2 cycles of a platinum-based CHT of choice</td>
<td>9.8</td>
<td>25</td>
<td>37% at 3 years</td>
</tr>
<tr>
<td>RADITUX; control arm (4)</td>
<td>51</td>
<td>66 Gy/24 fx</td>
<td>Cisplatin (6 mg/m² daily) concurrently with RT</td>
<td>11.8</td>
<td>28.7</td>
<td>32% at 5 years</td>
</tr>
<tr>
<td>RTOG 0617; control arm (5)</td>
<td>166</td>
<td>60 Gy/30 fx</td>
<td>Paclitaxel 45 mg/m² plus carboplatin weekly (AUC 2) concurrently with RT, followed by 2 cycles of paclitaxel (200 mg/m²) and carboplatin (AUC 6)</td>
<td>11.8</td>
<td>28.7</td>
<td>32% at 5 years</td>
</tr>
<tr>
<td>PET-Plan; experimental arm (6)</td>
<td>32</td>
<td>66.6–73.8 Gy/37–41 fx</td>
<td>Cisplatin (20 mg/m², d. 1–4 and 29–32) plus iv vinorelbine (15 mg/m², d. 1, 8, 29 and 36)</td>
<td>11</td>
<td>19.3</td>
<td>22% at 3 years</td>
</tr>
<tr>
<td>SOCCAR; CHRT arm (7)</td>
<td>70</td>
<td>55 Gy/20 fx</td>
<td>Cisplatin 20 mg/m² concurrently with RT fx 1–4 and 16–19, plus vinorelbine 15 mg/m² prior to RT fx 1, 6, 15 and 20</td>
<td>12.9</td>
<td>24*</td>
<td>32% at 3 years</td>
</tr>
<tr>
<td>START; CHRT plus tecemotide arm (8)</td>
<td>538</td>
<td>60–66 Gy/30–33 fx</td>
<td>At least 2 cycles of platinum-based CHT concurrently with RT followed by one dose of iv cyclophosphamide (300 mg/m²) 4–12 wks after CHRT and 3 days before tecemotide</td>
<td>10.0</td>
<td>30.8</td>
<td>30% at 5 years</td>
</tr>
<tr>
<td>START; CHRT plus placebo arm (8)</td>
<td>268</td>
<td>60–66 Gy/30–33 fx</td>
<td>At least 2 cycles of platinum-based CHT concurrently with RT</td>
<td>8.4</td>
<td>20.6</td>
<td>30% at 5 years</td>
</tr>
<tr>
<td>GILT; control arm (9)</td>
<td>105</td>
<td>66 Gy/33 fx</td>
<td>2 cycles of oral vinorelbine (50 mg/m² d.1, 8 and 15) plus cisplatin (20 mg/m² d. 1–4) q. 4 wks concurrently with RT</td>
<td>5.5</td>
<td>18.5</td>
<td>18% at 5 years</td>
</tr>
<tr>
<td>GILT; experimental arm (9)</td>
<td>96</td>
<td>66 Gy/33 fx</td>
<td>2 cycles of oral vinorelbine (50 mg/m² d. 1, 8 and 15) plus cisplatin (20 mg/m² d. 1–4) q. 4 wks concurrently with RT plus consolidation</td>
<td>6.4</td>
<td>20.8</td>
<td>20% at 5 years</td>
</tr>
<tr>
<td>PACIFIC; control arm (10)</td>
<td>236</td>
<td>54–66 Gy/27–33 fx</td>
<td>At least 2 cycles of platinum-based CHT concurrently with RT</td>
<td>5.6**</td>
<td>29.1**</td>
<td>43% at 3 years</td>
</tr>
</tbody>
</table>

*, data derived from survival curves; **, data calculated from randomization up to 42 days post RTCH completion.
that out of 115 patients who underwent $^{18}$F-FDG PET, 28 (24%) were excluded from planned therapy due to upstaging to stage IV. Stage migration in this group resulted in improved outcomes compared to subjects who did not undergo $^{18}$F-FDG PET (median OS of 22.3 and 11.3 months, respectively). A meta-analysis including studies of concurrent CHRT performed between 1988 and 2003, i.e., before the routine introduction of $^{18}$F-FDG PET and $^{18}$F-FDG PET-CT, showed a median OS of 18 months in stage III NSCLC (16). With the assumption of 20% to 30% upstaging to metastatic NSCLC by routine $^{18}$F-FDG PET imaging, and a 12-month median OS in stage IV, the estimated median OS of true stage III patients (PET negative for distant metastases) is in the range of 19.5 to 20.3 months. These values are still in a lower range of recent studies using concurrent CHRT (Table 1). For example, in the PROCLAIM trial comparing two CHT regimens combined with concurrent RT in stage III NSCLC, the post-hoc analysis showed the median OS of 27.2 and 20.8 months, respectively, in patients who did and did not undergo initial $^{18}$F-FDG PET-CT imaging (HR =0.81; P=0.13) (17).

Brain imaging

The incidence of asymptomatic brain metastases at presentation in stage III NSCLC ranges between 10% and 20%, and is relatively common in lung adenocarcinoma (18,19). Improved survival of locally advanced NSCLC by virtue of modern therapeutic approaches increases the risk of overt brain relapse. Currently, most specialized centers routinely perform brain imaging as a part of initial staging in patients considered for curative approaches. Since $^{18}$F-FDG PET-CT has low diagnostic accuracy for brain metastases, routine brain imaging includes CT or MRI; the latter identifying additional 4.7% of patients with brain dissemination compared to CT (20).

Invasive mediastinal lymph node staging

Although $^{18}$F-FDG PET-CT has greatly improved the diagnosis of hilar and mediastinal lymph node involvement in NSCLC, a proportion of stage III patients will need invasive staging of mediastinal lymph nodes. Indeed, the specificity of $^{18}$F-FDG PET-CT in mediastinal lymph node assessment ranges from 80% to 90%, with false-positive findings resulting mostly from coexisting inflammatory diseases such as sarcoidosis, antracosis or tuberculosis. Thus, EBUS and/or EUS TBNA, or mediastinoscopy are routinely used in these patients to exclude non-cancerous causes of $^{18}$F-FDG PET-CT positivity. More controversial is the use of EBUS/EUS TBNA prior to definitive CHRT in patients with $^{18}$F-FDG PET-CT negative lymph nodes. In cases with CT-enlarged (short axis above 10 mm) vs. normal lymph nodes, these invasive procedures decrease the risk of false-negative reading of $^{18}$F-FDG PET-CT by 10% and 5%, respectively (21). Such upstaging results in encompassing additional lymph node groups in RT planning, with presumed reduction of geographical miss. However, the real impact of invasive mediastinal staging in addition to $^{18}$F-FDG PET-CT on long-term outcomes in stage III NSCLC patients managed with CHRT is not well established.

Tumor volume and its dynamics

Currently, treatment strategy in locally advanced NSCLC is mainly based on tumor advancement and standard patient features, such as performance status and comorbidities. Novel high-precision technologies assessing tumor volume and its dynamics during RT may inform personalized treatment decisions. Examples of such opportunities are discussed below.

One of the basic assumptions in radiobiology is that the number of potential stem cells which must be sterilized is proportional to the tumor volume, and strongly affects the dose required to control the tumor (22). This implies consideration of dose corrections according to tumor size. Indeed, larger gross tumor volume (GTV) is associated with lower potential of cure and higher probability of distant metastases (23,24). Most of the dichotomous analyses using GTV cut-offs ranging from 45 to 200 cm$^3$ demonstrated strong prognostic impact of this measure (25). In the study of Bradley et al. (26), GTV was more predictive for OS than T category, N category and clinical stage. In a prospective TROG 99.05 trial, larger primary tumor was prognostic of death during the first 18 months, but not beyond (27). In another study, continuous increase of initial GTV (by 10 cm$^3$) impacted OS in univariate analysis, but in multivariate analysis this association was significant only in adenocarcinomas (28). Bradley et al. (26) hypothesized that the dose above 70 Gy may lead to improved cause-specific survival. This hypothesis was prospectively evaluated in the RTOG 0617 study discussed later in this review.

Currently, delineation of GTV in locally advanced NSCLC patients managed with definitive CHRT is
mostly based on $^{18}$F-FDG PET-CT. Hence, pretreatment volume of metabolically active tumor (MTV) may serve as prognostic factor and inform treatment modifications (29). In the study of Ohri et al. (30) median OS for patients with MTV below and above 95.4 cm$^3$ (determined as the optimal cutoff value) was 23.6 and 13.4 months, respectively (log-rank P<0.001). Median OS for those in the lowest, middle and highest tertile of MTV was 29.7, 21.2 and 13.6 months, respectively (P<0.001). In this study, MTV was also indicative for local control. In another study, two-year cumulative incidence rate of in-field progression for lesions below and above 25 cm$^3$ was 5% and 45%, respectively (P<0.001) (31). Pretreatment maximum $^{18}$F-FDG PET-CT standardized uptake value (SUVmax) of the primary tumor is associated with the probability of complete remission (32). In the study of Lee et al. (33) nodal SUVmax of less than 8 was correlated with improved PFS, distant metastasis-free survival and OS. Complex associations between PET findings and prognosis of NSCLC are discussed in the recent review of Brodin et al. 2020 (29).

A new therapeutic approach in locally advanced NSCLC is adaptive RT, employing temporal changes in the treatment plan delivered to the patient, according to anatomic changes caused by tumor shrinkage during RT. In the study of Kanzaki et al. (28), higher tumor reduction rate (defined as 1-GTV at the assessment time during treatment vs. initial GTV), correlated with better OS in squamous cell lung cancer (P=0.013), and with worse OS in adenocarcinoma (P=0.03). Koo et al. (34), in the study including 55% squamous cell lung cancers, showed a trend for poorer OS in subjects with larger volume reduction ratio (VRR) (HR =1.89; P=0.075). Likewise, in the study of Elsayad et al. (35), higher VRR after delivery of 40 Gy was predictive for poorer OS, particularly in non-adenocarcinoma patients. The authors hypothesized that high VRR may be indicative for more aggressive tumor behavior, as a fast response to CHRT is typical for small cell lung cancer.

Novel tools may facilitate objective tracking of tumor response during RT. Routinely used kilovoltage cone beam computed tomography (kV-CBCT) integrated into the linear accelerator, allows for on-line image guided RT. In the study of Wald et al. (36), greater reduction of GTV, sequenially assessed with kv-CBCT during the first four weeks of RT, was significantly associated with better distant control, PFS and OS. On the contrary, in the study of Kong et al. (37), mid-treatment decrease in MTV above mean was associated with shorter OS, but among patients who received mid-treatment MTV-adapted RT, OS was better in those with more than mean vs. less than mean MTV reduction (33 vs. 19 months, respectively). Interestingly, a recent study showed that higher tumor regression may be an adverse prognostic factor for CHRT, and a favorable prognostic factor for RT alone (38). Several studies have postulated the benefits of adaptive RT in locally advanced NSCLC (39-41). This approach is being investigated in the ongoing RTOG 1106 trial, results of which are expected shortly (42).

**Improvements of technique, dose and fractionation of radiotherapy**

Definitive RT has undergone significant progress, resulting in markedly improved therapeutic ratio. Increased biological effective dose (BED) with simultaneous protection of organs at risk (OAR) can be achieved with more precise definition of target volumes, use of conformal techniques, modification of dose and fractionation, and proper respiratory motion control.

**Techniques**

Historically, RT was planned using two-dimensional radiographs and bony landmarks with OAR protection by a cerrobend shielding. Imprecise visualization of target volumes required large RT fields to account for uncertainty, which resulted in noticeable toxicity. The advent of CT in the 1980s, and the widespread use of customized beam shaping with modern multileaf collimators (MLC), led to the development of three-dimensional conformal RT (3D-RT). This technique, which became the standard RT procedure in lung cancer, enables for precise and automatic beam shaping around a target volume and better shielding of OAR. 3D-RT also gives the opportunity to irradiate selectively involved lymph nodes with reduced target volumes. However, limited beam arrangements and uniform dose with this technique resulted in still high doses to OAR, especially in close proximity to the tumor.

The next, and one of the most important developments in RT techniques is intensity modulated RT (IMRT), which became commercially available in the beginning of 2000s. Its unique features include non-uniform intensity of the RT beams and computerized inverse planning. The beam modulation is provided through splitting a large RT field into small beamlets by the use of MLC with multiple narrow leafs moving during RT. Several beams build up a
highly conformal dose distribution. Computer algorithm optimize the fluence map by iterative calculations and advanced algorithms to achieve the optimal plan. IMRT enables for dose escalation with high precision and can produce intentional dose inhomogeneity for multiple integrated targets with different dose prescriptions, e.g., to minimize dose to OAR or to deliver simultaneous integrated boost.

Important and clinically relevant improvement of dosimetry with IMRT was reported in several studies. IMRT can reduce percentage of lung volume exposed to the dose equal to 20 Gy or more (V20Gy) by 15%, and esophageal V50Gy by 40% (43,44). There are no randomized studies comparing these two techniques in stage III NSCLC. However, numerous retrospective studies postulated clinical superiority of IMRT-based RT over conventional 3D-RT. In the study of Yom et al. (45), the incidence of grade 3 radiation pneumonitis at one year in stage III NSCLC patients who underwent CHRT with and without use of IMRT (n=68 and 222, respectively) was 8% vs. 32% respectively (P=0.002). Lower toxicity was achieved despite higher median GTV for IMRT plans (194 vs. 142 mL), and was attributed to lower V20Gy. Other retrospective study comparing 4D/IMRT vs. conventional 3D-RT showed significantly lower toxicity and improved OS with the former (median OS of 1.4 vs. 0.85 years, respectively P=0.039) (46). However, this improvement might have partly been due to stage migration, as more patients in the IMRT group were staged with 18F-FDG PET-CT. Hu et al., 2016 (47) performed an overview of retrospective studies to assess conventional 3D-RT and IMRT-based RT in terms of OS (five studies), radiation pneumonitis (four studies) and radiation esophagitis (four studies). OS with IMRT was improved in univariate, but not in multivariate analysis (HR =0.96; P=0.477). The use of IMRT reduced the incidence of grade 2 radiation pneumonitis [relative risk (RR) of 0.74; P=0.009], but increased the incidence of grade 3 radiation esophagitis (RR =2.47; P<0.001).

In the RTOG 0617 phase III trial that explored two doses of definitive RT with or without cetuximab, the choice of RT technique was at the discretion of investigators, and the baseline characteristics in patients treated with or without IMRT were uneven (48). The group treated with IMRT had, compared to those treated with other techniques, larger average planning tumor volume (PTV) (409 vs. 509 cm³, respectively), higher PTV/lungs volume ratio, and included more stage IIIB cases (43% vs. 31%, respectively). Despite these imbalances, IMRT resulted in less pulmonary and heart toxicity, and in lower decline of quality of life (21% vs. 46%, respectively). There was no difference though in OS between IMRT and conventional 3D-RT.

Steeper dose gradients make IMRT strongly dependent on target and OAR volume specification and is therefore less forgiving for target volume inaccuracies than conventional 3D-RT. Routine use of IMRT and closely related techniques, such as volumetric arc RT, is thus particularly dependent on proper disease staging, accurate contouring, motion management, and image guidance with cone-beam CT, to avoid geographical miss.

**Involved field irradiation**

Involved-field RT (IFRT) denotes the delivery of RT only to areas apparently involved by a tumor. Several large retrospective studies demonstrated that in NSCLC the risk of isolated out-of-field nodal recurrence with IFRT is in the range of only 1–6% (49-51). In the meta-analysis including three randomized clinical trials and three cohort studies, no significant difference was found in the incidence of elective nodal failure with the use of IFRT compared with ENI both in randomized trials (RR =1.38, 95% CI: 0.59–3.25; P=0.46), and in cohort studies (RR =0.99, 95% CI: 0.46–2.10; P=0.97) (52).

Two randomized clinical trials showed that selective RT of involved lymph nodes in stage III NSCLC can increase OS, possibly by virtue of dose escalation. In the first trial 200 patients were randomized to receive either IFRT (68–74 Gy in 2 Gy fractions) or ENI (60–64 Gy in 2 Gy fractions) (53). Two and five-year OS rates were 39.4% and 25.1%, respectively, with IFRT, and 25.6% and 18.3%, respectively, with ENI (the difference in two-year OS rate was significant at P=0.048). The limitations of this trial were single institution design and difference in RT doses between the arms. Other randomized trial compared IFRT (2.0 Gy daily for consecutive 5 days a week to the maximal tolerable dose) vs. maximal tolerable dose to GTV with the same fractionation, and ENI at a dose of 40–46 Gy (54). The median RT dose was 60 Gy (range, 38–74 Gy) in the IFRT arm, and 60 Gy (range, 32–70 Gy) in the ENI arm. More patients in the IFRT arm received at least 62 Gy (48.9% vs. 25.9% in the ENI arm; P=0.018). Three-year OS rates for IFRT and ENI were 36.6% and 30.3%, respectively (P=0.08). OS in patients who received at least 62 Gy in the IFRT arm was better than that in those administered doses below 62 Gy in both arms, and in those who received at
least 62 Gy in the ENI arm (P=0.013). These results, and the results of the previously mentioned PET-Plan trial (15), confirm the efficacy of highly conformal IFRT with steep dose gradients.

Dose and fractionation

The landmark RTOG 7301 trial established the dose of 60 Gy in 2 Gy fractions as the standard for definitive RT in locally advanced NSCLC (55). Abundant radiobiology data suggest positive association between tumor BED and survival. The traditional approach is to escalate the total dose by increasing number of fractions. Preliminary single-arm dose escalation trials speculated that escalating dose over 60 Gy using 2 Gy fractions may provide some survival benefit. The RTOG 9311 study, which stratified patients to receive escalating doses of 3D-RT depending on V20 parameter, showed that dose can be safely increased to 83.8 Gy (56). In the RTOG 0117 phase I/II trial, maximum tolerated dose was 74 Gy in 37 fractions (57). In the pivotal RTOG 0617 study, however, patients who received higher conventionally fractionated RT dose (74 Gy) combined with concomitant CHT had surprisingly worse OS than those administered standard dose of 60 Gy (median OS of 20.3 and 28.7 months, respectively) (48). Higher dose was also associated with lower quality of life at three months, and higher incidence of severe esophagitis (21% vs. 7% in the low-dose group). The most significant single factor for such a dramatic difference in favor of the 60 Gy appears to be radiation-induced toxicity, particularly cardiac toxicity in the high-dose arm. Additionally, concern regarding treatment toxicity may have prompted inappropriately tight radiation fields. Another aspect is repopulation during treatment toxicity may have prompted inappropriately tight radiation fields. Another aspect is repopulation during treatment time of CHRT is clearly not the way to go to improve treatment outcomes.

High BED without prolonging overall treatment time can be delivered with altered fractionation (hyperfractionation, accelerated fractionation or hypofractionation). RADITUX, a Dutch phase II trial investigating the impact of cetuximab combined with CHRT in stage III NSCLC, used IMRT at a dose of 66 Gy in 24 fractions (2.75 Gy per fraction) combined with daily cisplatin at a dose of 6 mg/m² (4). The trial used all modern diagnostic and staging techniques, including mandatory 18F-FDG PET-CT, MR brain imaging and invasive endoscopic procedures. There was no benefit from the addition of cetuximab, but results in both arms were impressive (median OS above 30 months, five-year OS of 37%). Another phase II trial showed feasibility of hypofractionated RT (55 Gy in 20 fractions, 2.75 Gy per fraction) with concurrent cisplatin and vinorelbine, with outcomes typical for stage III NSCLC (56). 18F-FDG PET-CT was mandated in this study, but brain imaging and IMRT were not routinely used. The randomized CHARTWEL study of hyperfractionated accelerated weekend-less RT (60 Gy in 40 fractions within 2.5 weeks) vs. conventional RT (66 Gy in 33 fractions over 6.5 weeks) with or without induction CHT showed no benefit of the shortened schedule (58). Hitherto, there are no data from randomized studies to support altered fractionation RT schedules with concurrent CHT in stage III NSCLC. More thorough review of fractionation RT schedules in locally advanced NSCLC will be addressed in another article of this issue of Translational Lung Cancer Research.

Motion management

Respiration-induced tumor motion is a major obstacle for achieving a precise RT of lung cancer. The most significant movement is in cranio-caudal direction (59), and lower parts of the lungs show higher motion amplitudes (60). Small, compared to larger tumors, are more mobile (61). Successful delivery of highly conformal RT depends on individual information about tumor movements, which is obtained by four-dimensional CT (4D-CT), with external marker to correlate tumor motion with respiratory cycle. For most patients, single 4D-CT for treatment planning is sufficient (62). 4D-CT planning is also the basis for tumor motion management techniques, such as deep inspiration breath hold, respiration gating (switching on RT when the target is in desired phase/position) or tumor tracking (beam follows the fiducials within the target during entire respiratory cycle). Motion management for RT of stage III NSCLC is discussed in detail in another article of this issue of Translational Lung Cancer Research.

Systemic therapy

Concurrent, compared to sequential CHT and RT, improves long-term OS in stage III NSCLC patients by approximately 5%, at the expense of increased toxicity, mainly acute esophagitis (16). This benefit is achieved through increased locoregional, but not systemic control. Currently, several CHT schedules are routinely employed in concomitant CHRT. Of those, two cycles of cisplatin-
etoposide or platinum-vinorelbine given every three weeks are well established and have been most commonly used in clinical trials included in the 2010 meta-analysis (16). The PROCLAIM phase III trial randomized patients with non-squamous stage III NSCLC to RT combined with either two cycles of concomitant cisplatin-etoposide followed by consolidation with platinum-based doublet, or concomitant cisplatin-pemetrexed followed by consolidation with pemetrexed (3). There was no OS or PFS difference between the study arms, but pemetrexed-based regimen was associated with lower incidence of grade 3–4 drug-related adverse events (64% vs. 77%, respectively), particularly grade 3–4 neutropenia (24.4% vs. 44.5%). Owing to this difference and easier logistics (fewer drug administrations), cisplatin-pemetrexed is currently used routinely as a part of CHRT for stage III non-squamous NSCLC. Another CHT schedule, weekly carboplatin and paclitaxel, is widely used in North America, including recent RTOG 0617 trial (5). Whereas radiosensitizing properties of carboplatin vs. cisplatin are still debated, this schedule is convenient due to relatively limited toxicity, and may be used in more fragile patients. However, a Chinese phase III trial demonstrated non-significantly worse OS in patients who received weekly carboplatin-paclitaxel compared to two cycles of cisplatin-etoposide every three weeks (median OS of 20.7 and 23.3 months, respectively; P=0.095) (63). Cisplatin-etoposide regimen was associated with significantly higher risk of grade 3–4 neutropenia, whereas the risk of radiation pneumonitis was significantly higher with paclitaxel-cisplatin. Similar OS and lower hematologic toxicity of paclitaxel-cisplatin was also found in earlier retrospective analysis comparing these two regimens (64). Likewise, in the systematic review of published trials both regimens were similarly effective (median OS of 19.6 and 18.4 months for cisplatin-etoposide and paclitaxel-cisplatin, respectively) (65). Hematological toxicity was higher for cisplatin-etoposide, and there was no difference in pulmonary toxicity. Thus, weekly carboplatin-paclitaxel combined with concomitant RT remains a viable option, particularly in patients with other comorbidities and still adequate pulmonary reserve. An effective option is also, developed almost three decades ago and still used, daily cisplatin at 6 mg/m² with concurrent hypofractionated RT (66 Gy in 24 fractions) (66).

Another approach to increase efficacy of CHRT is employing additional induction or consolidation systemic therapy (67). Studies using CHT before (68) or after CHRT (69-71) did not demonstrate improved outcomes, and showed increased toxicity with these approaches. Despite no clear benefit, consolidation docetaxel is still used in some centers, particularly after concurrent CHRT with weekly carboplatin-paclitaxel, with the rationale of inadequate systemic exposure with this regimen.

Likewise, no benefit was found with adjunctive targeted therapies. In the SWOG 0023 trial patients who completed CHRT and consolidation docetaxel were randomly assigned to gefitinib 250 mg daily or placebo (72). Surprisingly, the addition of gefitinib resulted in shorter OS compared to placebo (median OS of 23 and 35 months, respectively; P=0.013). In the previously mentioned RTOG 0617 study, that compared two doses of RT, patients were additionally assigned to cetuximab or placebo concurrently with CHRT and as consolidation. There was no benefit from EGFR blockade (median OS 25 and 24 months in cetuximab and placebo arms, respectively; P=0.58), whereas grade 3 or greater toxicity was higher in the former (86% vs. 70%, respectively) (48). The development of consolidation bevacizumab was terminated due excessive toxicity of this approach (73).

Currently, the only consolidation approach providing an apparent clinical benefit remains durvalumab, an anti-PD-L1 monoclonal antibody (10).

**Chemoradiation in elderly patients**

Most patients diagnosed with NSCLC are 65 or older, and the population of elderly people will continue to increase. Lung cancer patients have also multiple comorbidities and may not be amenable for aggressive therapeutic approaches such as CHRT. In a consecutive series of de Ruyscher et al. (74), the proportion of serious comorbidities in patients below and above 75 years was 47% and 63%, respectively. The eligibility rate for CHRT was 50% in the age group of 60–69, 41% in the age group of 70–74 years, and 0% in patients 75 years or older. Elderly patients have been poorly represented in controlled clinical trials of locally advanced NSCLC. The only randomized study designed for elderly patients with unresectable locally advanced NSCLC was terminated prematurely due to excessive toxicity (75).

Retrospective and subgroup analyses of randomized trials indicate that CHRT can still be an option for selected elderly patients. The RTOG 94-10 phase III trial compared sequential CHRT (induction cisplatin plus vinblastine followed by RT on day 50, SEQ) vs. two concurrent regimens: (cisplatin plus vinorelbine combined with 60 Gy
(CON-QD), or cisplatin plus etoposide combined with twice daily RT for a total dose of 69.6 Gy (CON-BID). Of the 610 patients enrolled, only 17% were 70 years or older. The median OS in the elderly subset was 22.4 months for CON-QD and 16.4 months for CON-BID, vs. 10.8 months for SEQ (P=0.069), whereas there was no notable difference in the younger group (median OS of 15.5, 16.0 and 15.7 months, respectively). However, the incidence of severe esophagitis with concomitant approach in elderly was higher (33% and 60%, for QD and BID, respectively) than in patients below 70 years (23% and 42%, respectively). Long-term toxicities were similar in both age groups (76).

In the randomized NCCTG trial 5-year survival rates with CHRT were 13% in patients aged 70 years or older vs. 18% in those below 70 years (P=0.4). Despite increased toxicity, elderly patients have survival rates equivalent to younger individuals (77). In the meta-analysis by Auperin et al. (16) the advantage of concomitant over sequential CHRT included also patients older than 70 years.

Data from the National Cancer Database indicate that CHRT (be sequential or concurrent) in elderly patients is more effective than RT alone, however sequential CHRT was superior to concurrent CHRT (HR =0.91, 95% CI: 0.85–0.96, P=0.002) (78).

On the other hand, pooled analysis of six RTOG studies showed that the best quality of life-adjusted survival in patients >70 years of age was observed with RT alone (79).

An ongoing PACIFIC 6 study investigates an option of sequential CRT followed by immunotherapy, which may be particularly relevant in the older population of patients (ClinicalTrials.gov identifier NCT03693300).

The EORTC Elderly Task Force and Lung Cancer Group, and International Society for Geriatric Oncology, recommend that treatment decisions should be based on patient characteristic and fit senior patients could benefit from concurrent CHRT (80). Clearly, a thorough patient selection including geriatric assessment may allow treatment optimization in this group of patients.

**Conclusions and future directions**

For almost two decades CHRT has constituted a therapeutic standard in locally advanced inoperable NSCLC. Compared to the results of the meta-analysis published 10 years ago (16), the efficacy of definitive CHRT for stage III NSCLC has markedly improved. A median OS of approximately 20–30 months, and five-year OS of approximately 30%, without consolidation immunotherapy, has been achieved. This progress has been predominantly due to improved staging, advanced RT technologies and restrictive quality control, and less due to more effective CHT. Indeed, local and regional control with CHRT is currently in the range of 80% and 90%, respectively (81), leaving a narrow margin for further improvement. On the other hand, around 40–50% of patients will relapse at distant sites, therefore increasing cure rate will necessitate more effective systemic therapies. A recent spectacular example of such approach is consolidation immunotherapy after definitive CHRT (10), the current therapeutic standard in inoperable stage III NSCLC.

**Acknowledgments**

**Funding:** None.

**Footnote**

**Provenance and Peer Review:** This article was commissioned by the editorial office, *Translational Lung Cancer Research* for the series “Radiotherapy in thoracic malignancies. The article has undergone external peer review.

**Reporting Checklist:** The authors have completed the Narrative Review reporting checklist. Available at [http://dx.doi.org/10.21037/tlcr-20-704](http://dx.doi.org/10.21037/tlcr-20-704)

**Peer Review File:** Available at [http://dx.doi.org/10.21037/tlcr-20-704](http://dx.doi.org/10.21037/tlcr-20-704)

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at [http://dx.doi.org/10.21037/tlcr-20-704](http://dx.doi.org/10.21037/tlcr-20-704)). The series “Radiotherapy in thoracic malignancies” was commissioned by the editorial office without any funding or sponsorship. RD served as the unpaid Guest Editor of the series. JJ served as the unpaid Guest Editor of the series and serves as an unpaid editorial board member of *Translational Lung Cancer Research* from Sep 2019 to Sep 2021. RD reports personal fees and other from Roche, personal fees and other from AstraZeneca, personal fees from Novartis, personal fees from Pfizer, personal fees from MSD, personal fees from Takeda, personal fees from Boehringer-Ingelheim, personal fees from Foundation Medicine, outside the submitted work. JJ reports Speaker: AstraZeneca, Roche, Pfizer; Advisory
roles: AstraZeneca, BMS, Pfizer, MSD, Takeda; Travel support: Roche, Pfizer. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


